Trial Profile
Delayed start study of donepezil hydrochloride for cognitive decline in Parkinson's disease following EDAP-1 [EXTENSION OF 700197202]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2021
Price :
$35
*
At a glance
- Drugs Donepezil (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms EDAP-2
- 22 Nov 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 24 Jan 2014 Status changed from recruiting to active, no longer recruiting according to University Hospital Medical Information Network-Japan record.
- 28 May 2013 New trial record